Real-world effectiveness of long-acting injectable vs. oral antipsychotics in patients with bipolar I disorder: a 1-year retrospective observational study

被引:0
作者
Korkmaz, Sukru Alperen [1 ,3 ]
Gurler, Sumeyye [2 ]
机构
[1] Canakkale Onsekiz Mart Univ, Dept Psychiat, Canakkale, Turkiye
[2] Ankara Bilkent City Hosp, Dept Neurol, Ankara, Turkiye
[3] Canakkale Onsekiz Mart Univ, Dept Psychiat, Canakkale Merkez, Turkiye
关键词
Antipsychotic depots; antipsychotic long-acting injection; bipolar disorder; maintenance treatment; relapse; rehospitalization; MAINTENANCE TREATMENT; PHARMACOLOGICAL-TREATMENTS; DOUBLE-BLIND; RISPERIDONE; LITHIUM; MEDICATION; PREVENTION; EFFICACY; COHORT;
D O I
10.1080/03007995.2024.2337685
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveLong-acting injectable (LAI) antipsychotics are recommended in the treatment non-adherence. Despite the widespread use of LAI antipsychotics, there is limited data on clinical outcomes in bipolar I disorder (BD-I) patients with real-world data. We aimed to compare BD-I patients treated with LAI and oral antipsychotics (OAP) in terms of treatment effectiveness in a 1-year follow-up period.MethodsThe study was conducted retrospectively with electronic health records of 116 BDI patients. The primary outcomes were whether patients in the LAI group and the OAP group differed in relapse, rehospitalization, emergency room (ER) visits, and all-cause treatment discontinuation at 1-year follow-up after a mania episode. Cox regression modeling was used to predict the recurrence of any mood episode and all-cause treatment discontinuation during follow-up. The secondary outcomes evaluated were the effects of sociodemographic and clinical parameters and concomitant psychotropic medications on the course of the illness and treatment adherence.ResultsOf all 116 patients, 33 (28.4%) were under LAI, and 83 (71.6%) were under OAP treatment. LAI users had a history of more hospitalizations and total mood episodes. Patients in the LAI group had more treatment non-adherence before the index hospitalization. At 1-year follow-up, there was no difference between the groups in terms of any mood relapse, rehospitalization, ER visits, and all-cause treatment discontinuation. As a secondary outcome, lithium users were found to have fewer new episodes and discontinuations of treatments.ConclusionsIn real-world data, there is no evidence that LAI antipsychotics (compared to OAP) are superior in the maintenance treatment of BD. These results are important in terms of reflecting clinical practices for the treatment of BD-I. These results do not devalue the use of LAI therapy in BD; however, more studies are needed to identify positive predictors for LAI treatments in BD.
引用
收藏
页码:855 / 861
页数:7
相关论文
共 34 条
  • [1] Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies
    Bartoli, Francesco
    Cavaleri, Daniele
    Nasti, Christian
    Palpella, Dario
    Guzzi, Pierluca
    Riboldi, Ilaria
    Crocamo, Cristina
    Pappa, Sofia
    Carra, Giuseppe
    [J]. THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2023, 13
  • [2] Effect of long-acting injectable antipsychotics on 1-year hospitalization in bipolar disorder: a mirror-image study
    Bartoli, Francesco
    Callovini, Tommaso
    Cavaleri, Daniele
    Crocamo, Cristina
    Riboldi, Ilaria
    Aguglia, Andrea
    De Fazio, Pasquale
    Martinotti, Giovanni
    D'Agostino, Armando
    Ostuzzi, Giovanni
    Barbui, Corrado
    Carra, Giuseppe
    [J]. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2023, 273 (07) : 1579 - 1586
  • [3] Long-acting injectable antipsychotics as maintenance treatments for bipolar disorderA critical review of the evidence
    Boyce, Philip
    Irwin, Lauren
    Morris, Grace
    Hamilton, Amber
    Mulder, Roger
    Malhi, Gin S.
    Porter, Richard J.
    [J]. BIPOLAR DISORDERS, 2018, 20 : 25 - 36
  • [4] Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study
    Calabrese, Joseph R.
    Sanchez, Raymond
    Jin, Na
    Amatniek, Joan
    Cox, Kevin
    Johnson, Brian
    Perry, Pamela
    Hertel, Peter
    Such, Pedro
    Salzman, Phyllis M.
    McQuade, Robert D.
    Nyilas, Margaretta
    Carson, William H.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2017, 78 (03) : 324 - +
  • [5] Clinical outcomes of long-acting injectable risperidone in patients with bipolar I disorder: A 1-year retrospective cohort study
    Chan, Hsue-Wei
    Huang, Chin-Yu
    Feng, Wen-Jui
    Yen, Yung-Chieh
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2016, 205 : 360 - 364
  • [6] The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines
    Fountoulakis, Konstantinos N.
    Grunze, Heinz
    Vieta, Eduard
    Young, Allan
    Yatham, Lakshmi
    Blier, Pierre
    Kasper, Siegfried
    Moeller, Hans Jurgen
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2017, 20 (02) : 180 - 195
  • [7] Long-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder
    Gigante, Alexandre Duarte
    Lafer, Beny
    Yatham, Lakshmi N.
    [J]. CNS DRUGS, 2012, 26 (05) : 403 - 420
  • [8] Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology
    Goodwin, G. M.
    Haddad, P. M.
    Ferrier, I. N.
    Aronson, J. K.
    Barnes, T. R. H.
    Cipriani, A.
    Coghill, D. R.
    Fazel, S.
    Geddes, J. R.
    Grunze, H.
    Holmes, E. A.
    Howes, O.
    Hudson, S.
    Hunt, N.
    Jones, I.
    Macmillan, I. C.
    McAllister-Williams, H.
    Miklowitz, D. R.
    Morriss, R.
    Munafo, M.
    Paton, C.
    Saharkian, B. J.
    Saunders, K. E. A.
    Sinclair, J. M. A.
    Taylor, D.
    Vieta, E.
    Young, A. H.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2016, 30 (06) : 495 - 553
  • [9] Preventive effect of aripiprazole once monthly on rehospitalization for bipolar disorder: A multicenter 1-year retrospective mirror image study
    Goto, Junichi
    Shono, Masahiro
    Abe, Yasuhisa
    Fujita, Yasutaka
    Ueda, Keishi
    Yoshida, Binchi
    Nabeshima, Yoshihiro
    [J]. NEUROPSYCHOPHARMACOLOGY REPORTS, 2023, 43 (03) : 425 - 433
  • [10] Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records
    Hayes, Joseph F.
    Marston, Louise
    Walters, Kate
    Geddes, John R.
    King, Michael
    Osborn, David P. J.
    [J]. WORLD PSYCHIATRY, 2016, 15 (01) : 53 - 58